Showing 5061-5070 of 7024 results for "".
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- Analysis: Lower PsA Risk Linked to Psoriasis Treatment Target Achievementhttps://practicaldermatology.com/news/lower-psa-risk-linked-to-psoriasis-treatment-target-achievement/2471577/Patients with psoriasis who achieve the National Psoriasis Foundation (NPF) treatment target after starting biologic therapy may experience a reduced risk of developing psoriatic arthritis (PsA), according to findings from the CorEvitas Psoriasis Registry.
- Evolving Approaches to Treating Melasma Highlighted at AADhttps://practicaldermatology.com/news/Evolving-Approaches-Treating-Melasma-Highlighted-AAD/2471546/Use of imaging and aggressive treatment are critical in the medical management of melasma in 2025, Mukta Bhardwaj Sachdev,MD, IFAAD, said at the 2025 American Academy of Dermatology (AAD) Annuel Meeting in Orlando, Florida. “You need to use imaging systems, monitor your patients, [use] top
- Novel TYK2 Inhibitor Shows Promising Results in Phase 2 Trials for PsOhttps://practicaldermatology.com/news/Novel-TYK2-Inhibitor-Shows-Promising-Results-Phase-2-Trials-PsO/2471545/The TYK2 inhibitor ESK-001 has shown promising safety and efficacy in long-term Phase 2 trials for moderate-to-severe plaque psoriasis, Andrew Blauvelt, MD, FAAD, said in a late-breaking research presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- AAD Posters Highlight Positive Data for Roflumilasthttps://practicaldermatology.com/news/AAD-Posters-Highlight-Positive-Data-Roflumilast/2471539/Arcutis Biotherapeutics, Inc., announced new data from two posters shared at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The first poster presentation details the positive efficacy, patient-reported outcomes, and tolerability for the use of once-daily
- Treat the Whole Patient: Enhancing Care in Pediatric Alopecia Areatahttps://practicaldermatology.com/news/enhancing-care-for-pediatric-alopecia-patients/2471536/Understanding and treating pediatric alopecia areata (AA), and its impact on the emotional and social lives of children and young people, was the subject of a presentation by dermatologist Brittany Craiglow, MD, PhD, FAAD. Addr
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- JAK Inhibitors' Applications Continue to Expandhttps://practicaldermatology.com/news/JAK-Inhibitors-Applications-Continue-Expand/2471523/While JAK inhibitors have become widely popular for several common skin diseases, their potential for other indications remains vast, and Ruth Ann Vleugels, MD, MPA, MPH, FAAD, highlighted some of these in “JAK Inhibitors for Lupus, Dermatomyositis, and SAVI” at the 2025 American Academy of Derma